Insider Transactions in Q1 2022 at An2 Therapeutics, Inc. (ANTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
Kabeer Aziz |
BUY
Open market or private purchase
|
Indirect |
166,666
+7.01%
|
$2,499,990
$15.0 P/Share
|
|
Mar 29
2022
|
Kabeer Aziz |
BUY
Conversion of derivative security
|
Indirect |
2,430,714
+33.05%
|
-
|
|
Mar 29
2022
|
Eric Easom Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,907
+50.0%
|
-
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Open market or private purchase
|
Indirect |
166,666
+7.01%
|
$2,499,990
$15.0 P/Share
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,430,714
+33.05%
|
-
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
153,334
+14.49%
|
$2,300,010
$15.0 P/Share
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Conversion of derivative security
|
Indirect |
751,621
+32.53%
|
-
|
|
Mar 29
2022
|
Joseph S Zakrzewski |
BUY
Conversion of derivative security
|
Direct |
98,199
+50.0%
|
-
|
|
Mar 29
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+27.03%
|
$24,999,990
$15.0 P/Share
|
|
Mar 29
2022
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,999,997
+50.0%
|
-
|